IMPORTANCE Inherited leukodystrophies are a group of neurological diseases affecting myelin that cause significant morbidities and death. Timely and correct diagnosis is important for initiating treatment, designing disease screening, and offering care and guidance to patients and families.
Introduction
Inherited leukodystrophies are a group of diseases affecting myelin that cause significant morbidities and death in 1 of 3 patients by age 8 years. 1 Because certain leukodystrophies are clinically distinct, are uniquely diagnosable, and are the subject of extensive outcome and genetic studies, they have the potential to serve as an important proxy for understanding issues related to diagnosis and treatment in pediatric neurological and orphan diseases. Furthermore, children with neurological impairment, including leukodystrophies, account for a large and growing proportion of children's hospital charges (30%). 2 Over the past 2 decades, estimates of the incidence of leukodystrophies have been performed with varying methods at tertiary referral centers and population-based medical centers, as well as using national databases. 1, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] However, a major limitation is that almost all studies of disease prevalence, outcomes, burden, and treatment have been performed in the United States or Europe, with patients drawn from predominantly Caucasian ancestry. 1, 3 To our knowledge, the incidence of leukodystrophies in racial/ethnic minority patient populations has not been examined, and it is not known whether diagnosis rates are equivalent in racial/ethnic minority populations, whether mutation rates are similar, and whether disease presentation or response to treatment differ.
Because some leukodystrophies are treatable but require timely diagnosis and have therefore been added to newborn screening, 13 understanding ethnic and racial differences is critical for effective screening, diagnosis, and treatment. Our objective was to determine whether there are disparities in leukodystrophy diagnosis in different racial backgrounds.
Methods
This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline for cohort analyses. 14 The study, which used deidentified data, was not considered human subjects research and was exempted by the institutional review boards at the University of Utah 
Statistical Analysis
Patients with leukodystrophies were identified from any PHIS visit (inpatient, observation, We estimated the 2-year point prevalence of composite and individual leukodystrophy diagnoses in racial groups using a generalized linear model with a binomial distribution and logit linkage function. We fit the model with generalized estimating equations to account for correlation between patients within the same hospital. We estimated unadjusted and adjusted point estimates.
Adjusted prevalence estimates were obtained by controlling for sex, insurance, urban or rural status, 2010 median household income for patient zip code, number of inpatient days, and age at first PHIS visit. All analyses were 2-sided, and P < .05 was considered statistically significant. Statistical analyses were conducted with SAS statistical software version 9.4 (SAS Institute Inc).
To compare leukodystrophy gene allele frequencies in different racial groups, we calculated missense and loss-of-function frequencies using the gnomAD database 16 for ABCD1, ARSA, GALC, and IDUA. We used a Kruskal-Wallis test to determine significance with subsequent χ 2 analysis.
Results
We reduced rate of diagnosis was out of proportion to the frequency of the different races in PHIS. When each leukodystrophy was singly tested, nonwhite race was also associated with not having a diagnosis (Table 2) .
To explore whether lower leukodystrophy gene allele frequencies in nonwhite races might account for lower diagnosis rates, we determined the frequency of missense and loss-of-function alleles in ABCD1, ARSA, GALC, and IDUA ( Figure) using the gnomAD database. 16 We 
Discussion
We found that patients of racial/ethnic minorities, including those from black, black Hispanic, and white Hispanic backgrounds, were significantly less likely to be diagnosed with a leukodystrophy.
Furthermore, we observed that leukodystrophy disease-associated allele frequencies were the same or higher in populations of Latino or African descent.
There are known examples of genetic founder effects for specific leukodystrophies in some populations. For example, there is a single historical origin of the mutation in ARSA causing MLD in patients of Arabic heritage 17 and there is a single origin from the 19th century causing a higher rate of MLD in the western Navajo Nation. 18 However, our observation of comparable or higher frequencies of disease gene alleles in different racial backgrounds suggests that a genetic founder effect is unlikely to account for the observed differences in diagnosis.
Strengths of this study are the use of specific ICD-10 codes to track specific leukodystrophy diseases. In the past, tracking outcomes for patients with leukodystrophies has been more difficult because ICD-9 codes have a relatively low specificity to the diagnosis of an inherited leukodystrophy, and relatively complex algorithms had to be used. 19 With the use of ICD-10 codes for X-linked adrenoleukodystrophy, MLD, Krabbe disease, and Hurler disease, we were able to track and compare specific leukodystrophies, which would not have been possible using ICD-9 coding or other less specific ICD-10 codes. Finally, the use of the PHIS national database provides a more comprehensive view of trends across the United States for these relatively rare diseases.
Limitations
Limitations for this study are its use of retrospective data and the limited duration of data collection.
The time limitation was necessary because ICD-10 has only been in use for the past 3 years, and ICD-10 code use was necessary to have sufficient specificity in determining diagnoses. We cannot exclude the possibility that the differences observed in diagnosis were related to different rates of hospital admission. For example, perhaps black patients with leukodystrophies were admitted less often to the hospital, or their families did not bring them to the emergency department as often.
Another limitation is that PHIS consists primarily of in-hospital data, with less outpatient clinic data, so it is not possible to accurately determine population rates of disease or prevalence. Our analysis of leukodystrophy gene allele frequencies used the data deposited in gnomAD, which may not have the same racial group distributions as PHIS. Further work should be done to better understand the nonwhite distribution of patients with leukodystrophies; because many patients with leukodystrophies report multiple for racial categorization, it is unclear whether this reflects interracial heritage or whether it is due to issues inherent in data collection. 
